Seres Therapeutics, Inc. (MCRB), founded in 2010, is a leading microbiome therapeutics platform company based in Cambridge, Massachusetts. Their pioneering work is centered on developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural balance of the gut’s microbes has got disrupted. This unique and innovative approach to therapeutics positions the company at the forefront of biological drug development, harnessing the power of the microbiome to treat illnesses.
The company's unique understanding of the human microbiome, coupled with its proprietary discovery and design platform, allows it to effectively identify, select, and cultivate specific bacterial strains with key biological functions that can directly impact human health. This fascinating new realm of scientific research has shown that the microbiome, the about 100 trillion microorganisms (bacteria, fungi, viruses, etc.) that live inside and on the human body, plays a crucial role in human health and disease.
Seres Therapeutics' primary focus is creating Ecobiotic drugs, a new category of medicines consisting of ecological compositions of beneficial organisms that are designed to functionally correct microbiome dysbiosis. They are developing potential treatments for a range of diseases, including inflammatory bowel disease (IBD), Clostridium difficile infection (CDI), and metabolic diseases like diabetes.
The company's most advanced program, SER-109, is under Phase 3 development for reducing recurrent C. difficile infection. Another program, SER-287, is being studied for the treatment of ulcerative colitis, one of the two main forms of IBD. Also on the horizon is SER-301, an oral capsule that is under development for the treatment of ulcerative colitis as well.
Seres Therapeutics, Inc. has also established collaborations in the scientific and academic communities to accelerate microbiome research and development. They have partnerships with world-renowned health institutions, including the Mayo Clinic, Memorial Sloan Kettering Cancer Center, and Massachusetts General Hospital. In addition, they are part of the consortium working on the National Institutes of Health’s Human Microbiome Project.
As a leader in microbiome therapeutics, Seres Therapeutics, Inc. continues to push boundaries in the biopharmaceutical industry with its unique approach to treating disease. By harnessing the power and potential of the microbiome, they are bringing forth a new era in medicine that holds promising potential for improving health and addressing unmet medical needs worldwide.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Seres Therapeutics announced the publication of its SER-155 Phase 1b clinical study results in Nature Medicine, demonstrating a 77% relative risk reduction in bloodstream infections (BSIs) for adults undergoing allogeneic hematopoietic cell transplantation. The investigational live biotherapeutic product also showed significantly lower systemic antibiotic exposure and improved biomarkers for gut barrier integrity and systemic inflammation. SER-155 has received Breakthrough Therapy and Fast Track designations from the FDA and is Phase 2-ready, pending funding.
Seres Therapeutics announced the publication of Phase 1b results for SER-155 in Nature Medicine, showing a 77% relative risk reduction in bloodstream infections among allogeneic hematopoietic cell transplantation recipients compared to placebo. The study also demonstrated significantly lower systemic antibiotic exposure and supported SER-155's mechanisms of strengthening the gut barrier and reducing inflammation. SER-155 has FDA Breakthrough Therapy and Fast Track designations and is Phase 2-ready, pending funding.
Seres Therapeutics, Inc. announced that its Compensation and Talent Committee granted inducement equity awards to two new employees on September 4, 2026. These grants consist of stock options to purchase 4,200 shares of common stock, with an exercise price of $5.72 per share. The awards were made under the Seres Therapeutics, Inc. 2022 Employment Inducement Award Plan, specifically for new hires, in compliance with Nasdaq Listing Rule 5635(c)(4).